| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Prepaid expenses | NaN | 2,298,704 | 2,099,491 | 1,614,226 |
| Cash & cash equivalents | 979,534 | 1,636,655 | 6,986,617 | 8,735,323 |
| Restricted cash | 8,000,000 | 8,000,000 | NaN | NaN |
| Short term investments | 1,500,000 | 2,000,000 | NaN | NaN |
| Prepaid expenses | 2,625,169 | NaN | NaN | NaN |
| Other current assets | 48,500 | 48,500 | NaN | NaN |
| Total current assets | 13,153,203 | 13,983,859 | 9,086,108 | 10,349,549 |
| Digital assets, at fair value | 127,815,173 | 149,885,371 | NaN | NaN |
| Long-term portion of prepaid expenses | 22,410 | 75,485 | 129,740 | 183,995 |
| Operating lease rou asset, net | 171,779 | 187,395 | NaN | NaN |
| Property and equipment, net | 56,592 | 51,626 | 34,188 | 13,137 |
| Total assets | 141,219,157 | 164,183,736 | 9,250,036 | 10,546,681 |
| Warrant liability | NaN | NaN | NaN | 174,413 |
| Accounts payable and accrued expenses | 2,978,190 | 918,649 | 567,633 | 119,138 |
| Accrued offering costs | 575,000 | 500,000 | NaN | NaN |
| Accrued interest - related party | 36,339 | 27,952 | 21,651 | 15,351 |
| Advance payable to related party | 12,000 | 12,000 | 100 | 100 |
| Notes payable - related party | 500,100 | 500,100 | 500,000 | 500,000 |
| Notes payable, net | 920,000 | NaN | NaN | NaN |
| Derivative liability | 1,568,634 | 1,616,913 | NaN | NaN |
| Convertible notes, net | 7,942,281 | 7,091,263 | NaN | NaN |
| Operating lease liability | 52,339 | 39,578 | NaN | NaN |
| Total current liabilities | 14,584,883 | 10,706,455 | 1,089,384 | 809,002 |
| Long-term convertible notes payable related party | NaN | NaN | NaN | 0 |
| Long-term portion of operating lease liability | 118,815 | 129,454 | NaN | NaN |
| Total liabilities | 14,703,698 | 10,835,909 | 1,089,384 | 809,002 |
| Preferred stock, par value 0.01, 10,000,000 shares authorized 7,477,017 issued and outstanding on march 31, 2026, and december 31, 2025, | 74,770 | 74,770 | NaN | NaN |
| Common stock, par value 0.01, 100,000,000 shares authorized 12,575,983 issued and outstanding as of march 31, 2026 and december 31, 2025, respectively | 125,760 | 125,760 | 125,760 | 125,760 |
| Common shares to be issued | 8,113,318 | NaN | NaN | NaN |
| Additional paid-in capital | 163,654,524 | 163,540,358 | 17,272,661 | 17,068,433 |
| Accumulated deficit | -45,452,913 | -10,393,061 | -9,237,769 | -7,456,514 |
| Total shareholders equity | 126,515,459 | 153,347,827 | 8,160,652 | 9,737,679 |
| Total liabilities and shareholders equity | 141,219,157 | 164,183,736 | 9,250,036 | 10,546,681 |
Apimeds Pharmaceuticals US, Inc. (APUS)
Apimeds Pharmaceuticals US, Inc. (APUS)